Roche struck a deal with Dualitas to accelerate next-generation bispecific antibody discovery in inflammatory and immunology settings. The collaboration centers on high-throughput screening of roughly 300,000 new bispecific combinations. Dualitas will deploy its discovery platform to identify candidates with differentiation potential in immune-mediated diseases, while Roche advances its broader strategy to expand its bispecific pipeline. The agreement underscores continued pharma reliance on specialist discovery partners to broaden hit rates and shorten early development timelines.